Teva: John Nason
Teva has placed John Nason in charge of the production of active pharmaceutical ingredients (APIs) and biologics, in the position of president of Teva Active Pharmaceutical Ingredients. The move for Nason represents a promotion from within the company, as he moves on from his previous role as SVP of European technical operations that he had performed at Teva over the previous three and a half years.
Having responsibility over both small and large molecule portfolios will not be a new experience for Nason, who previously worked at Bristol-Myers Squibb as vice president of external manufacturing and alliance management. In this position, he was leader for BMS global contract manufacturing organisations (CMOs) that produced both small and large molecule medicines.
“John’s deep technical expertise and strong track record distinguish him as a global leader who is exceptionally qualified for this pivotal role,” said Carlo de Notaristefani, EVP of Teva Global Operations. “I am confident in John’s ability to strengthen and grow these vital business assets for Teva and fully realise their potential to help patients and deliver for our customers around the world.”
